



SECOND PTO FORM-1449		Inventor: FUCHSS		Art Unit: 1625	
INFORMATION DISCLOSURE		Appl. No.: 10/573,203		Examiner: Rahmani, N.	
CITATION		Filing Date: 3/24/2006		Conf. No: 1948	
U.S. PATENT DOCUMENTS					
Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
NR	A1	7,138,399 (corresponds to WO03/080607)	11/21/2006	Ulrich	3/25/2003
FOREIGN PATENT DOCUMENTS					
Exam. Initial		Document No.	Public. Date	Country	Translation
NR	A2	2005/030769 A1	4/7/2005	WO	N/A
P	A3	2005/030771 A1	4/7/2005	WO	N/A
P	A4	2005/030770 A1	4/7/2005	WO	N/A
P	A5	2005/061496 A1	7/7/2005	WO	N/A
P	A6	97/25030 A1	7/17/1997	WO	N/A
P	A7	03/080607 A1	10/2/2003	WO	N/A
OTHER					
Exam. Initial					
P	A8	Hua, L.L., et al., "Role of mitogen-activated protein kinases in inducible nitric oxide synthase and TNF α expression in human fetal astrocytes", <u>Journal of Neuroimmunology</u> , Vol. 126, Pgs. 180-189, (2002).			
P	A9	Kim, M-S, et al., "Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid β peptide and interleukin- 1β ", <u>Neuroscience Letters</u> , Vol. 321, Pgs. 105-109, (2002).			
P	A10	Sautebin, L., "Prostaglandins and nitric oxide as molecular targets for anti-inflammatory therapy", <u>Fitoterapia</u> , Vol. 71, Pgs. S48-S57, (2000).			

10-09-07

NA	A11	Ohtsuka, M., et al., "PPA250 [3-(2,4-Difluorophenyl)-6-{2-[4-(1H-imidazol-1-ylmethyl)Phenoxy]ethoxy}-2-phenylpyridine], a Novel Orally Effective Inhibitor of the Dimerization of Inducible Nitric-Oxide Synthase, Exhibits an Anti-Inflammatory Effect in Animal Models of Chronic Arthritis", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , Vol. 303, No. 1, Pgs. 52-57, (2002).
2	A12	Hansel, T. T., et al., "A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics", <u>FASEB J</u> , Vol. 17, Pgs. 1298-1300, (2003).
P	A13	Tinker, A. C., et al., "1,2-Dihydro-4-quinazolinamines: Potent, Highly Selective Inhibitors of Inducible Nitric Oxide Synthase Which Show Antiinflammatory Activity in Vivo", <u>J. Med. Chem.</u> , Vol. 46, Pgs. 913-916, (2003).
P	A14	Kankuri, E., et al., "Suppression of Acute Experimental Colitis by a Highly Selective Inducible Nitric-Oxide Synthase Inhibitor, N-[3-(Aminomethyl)benzyl]acetamidine", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , Vol. 298, No. 3, Pgs. 1128-1132, (2001).
P	A15	Liu, Z-Q, et al., "Specificity of inducible nitric-oxide synthase inhibitors: prospects for their clinical therapy", <u>Acta Pharmacol Sin</u> , Vol. 20, No. 11, Pgs. 1052-1056, (1999).
P	A16	Salvemini, D., et al., "Dual Inhibition of Nitric Oxide and Prostaglandin Production Contributes to the Antiinflammatory Properties of Nitric Oxide Synthase Inhibitors", <u>J. Clin. Invest.</u> , Vol. 96, Pgs. 301-308, (1995).
P	A17	Cuzzocrea, S., et al., "Beneficial effects of GW274150, a novel, potent and selective inhibitor of INOA activity, in a rodent model of collagen-induced arthritis", <u>European Journal of Pharmacology</u> , Vol. 453, Pgs. 119-129, (2002).

Examiner

R

Date Considered

10-09-07

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.